Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 3.0 mg subcutaneous once weekly
DULA_SC_3p0MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.0 mg injection once weekly
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.00 (-6.42 to 3.00) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.10 (0.00 to 2.37) | 0.70 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.15 (0.02 to 0.92) | 0.86 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.00 (-9.86 to 3.91) | 0.55 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.75 (0.47 to 1.21) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.57 (0.73 to 3.28) | 0.51 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.33 (1.94 to 5.56) | 0.41 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.74 (2.01 to 7.00) | 0.39 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.58 (1.61 to 4.19) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.56 (1.28 to 5.03) | 0.32 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 1.21 (0.17 to 7.36) | 0.39 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.77 (0.04 to 11.54) | 0.51 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.70 (0.04 to 10.93) | 0.49 |
Trials
- AWARD-11A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus2018 · 1,842 randomized · 52 weeks
- NCT00791479Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions2008 · 167 randomized · 12 weeks